Growth Hormone Deficiency

GHD-Attribute Measure (GHD-ATM)

Copyright: Mery Brod, The Brod Group

Disease / Condition: growth hormone deficiency (GHD)

Population, Age: children diagnosed with GHD aged ≥ 10 years to ≤ 12 years and caregivers of children diagnosed with GHD aged ≥ 3 years to ≤ 12 years

Type of Clinical Outcome Assessment: Attribute measure (self-report) (child and caregiver versions); caregiver version has two ObsRO questions.

Outcome assessed: Treatment attributes; intended for use when treatment comparisons are not available.

  • Dimensions covered by the survey: growth hormone deficiency treatment preferences
    Number of items: 16; child and caregiver versions’ items are conceptually equivalent.
    Recall: current
    Language of Development: English for USA

    1. ‍Brod, M., Pfeiffer, K.M., Alolga, S.L., Beck, J.F., Murphy, M., Bruchey, A.K., Maniatis, A., Pitukcheewanont, P. Developing a Process for Preference Measures in Pediatric Growth Hormone Deficiency: Challenges and Solutions. Patient Prefer Adherence. 2025 May 8;19:1365-1384. doi: 10.2147/PPA.S500330.

  • Description text goes here

For more information on this measure, for use and/or licensing, contact Dr. Brod at (+1) 415 381 5532 or at mbrod@thebrodgroup.net or by filling out the CONTACT FORM.

GHD-Preference Measure (GHD-PRM)

Copyright: Mery Brod, The Brod Group

Disease / Condition: growth hormone deficiency (GHD)

Population, Age: children diagnosed with GHD aged ≥ 10 years to ≤ 12 years and caregivers of children diagnosed with GHD aged ≥ 3 years to ≤ 12 years

Type of Clinical Outcome Assessment: Preference measure (self-report) (child and caregiver versions); caregiver version has two ObsRO questions.

Outcome assessed: Treatment preferences; intended to be used when the respondent had experienced 2 different treatment options,

  • Dimensions covered by the survey: growth hormone deficiency treatment preferences
    Number of items:
    Child version (n=20); Caregiver version (n=31)
    Both versions share 20 conceptually equivalent items.
    Recall: current
    Language of Development: English for USA

    1. ‍Brod, M., Pfeiffer, K.M., Alolga, S.L., Beck, J.F., Murphy, M., Bruchey, A.K., Maniatis, A., Pitukcheewanont, P. Developing a Process for Preference Measures in Pediatric Growth Hormone Deficiency: Challenges and Solutions. Patient Prefer Adherence. 2025 May 8;19:1365-1384. doi: 10.2147/PPA.S500330.

  • Description text goes here

For more information on this measure, for use and/or licensing, contact Dr. Brod at (+1) 415 381 5532 or at mbrod@thebrodgroup.net or by filling out the CONTACT FORM.

Growth Hormone Deficiency - Child Impact Measure (GHD-CIM)

Copyright: Novo Nordisk

Disease / Condition: growth hormone deficiency (GHD)

Population, Age: children diagnosed with GHD aged 4 to < 13 years (respondent: adult parent/guardian)

Type of Clinical Outcome Assessment: ObsRO measure

Outcome assessed: health-related quality of life

  • Domains (n=3): Physical functioning, Social well-being, and Emotional well-being
    Number of items: 11
    Recall: past week
    Language of Development: English for USA

    1. Brod, M., Alolga, S.L., Beck, J.F., Wilkinson, L., Højbjerre, L., Rasmussen, M.H. Understanding burden of illness for child growth hormone deficiency.Qual Life Res. 2017;26(7):1673–86. doi: 10.1007/s11136-017-1529-1.

    2. Brod, M., Hojby Rasmussen, M., Vad, K., Alolga, S., Bushnell, D.M., Bedoin, J., Maniatis, A. Psychometric validation of the Growth Hormone Deficiency-Child Impact Measure (GHD-CIM). Pharmacoecon Open. 2021 Jan 12. doi: 10.1007/s41669-020-00252-5.

  • Contact Mapi Research Trust.

For more information on this measure, for use and/or licensing, contact Mapi Research Trust.

Growth Hormone Deficiency - Child Treatment Burden Measure - Child (GHD-CTB - Child)

Copyright: Novo Nordisk

Disease / Condition: growth hormone deficiency (GHD)

Population, Age: children diagnosed with growth hormone deficiency, 9 to < 13 years of age

Type of Clinical Outcome Assessment: PRO measure

Outcome assessed: treatment burden

  • Domains (n=3): Physical, Emotional well-being, and Interference
    Number of items: 14
    Recall: past week (7 days)
    Language of Development: English for USA

    1. Brod, M., Højbjerre, L., Alolga, S.L., Beck, J.F., Wilkinson, L., Rasmussen, M.H. Understanding treatment burden for children treated for growth hormone deficiency.Patient. 2017 Oct;10(5):653-666. doi: 10.1007/s40271-017-0237-9.

    2. Brod, M., Rasmussen, M.H., Alolga, S., Beck, J.F., Bushnell, D.M., Lee, K.W., Maniatis, A. Psychometric validation of the Growth Hormone Deficiency-Child Treatment Burden Measure (GHD-CTB) and the Growth Hormone Deficiency-Parent Treatment Burden Measure (GHD-PTB). Pharmacoecon Open. 2023 Jan;7(1):121-138. doi: 10.1007/s41669-022-00373-z.

  • Contact Mapi Research Trust.

For more information on this measure, for use and/or licensing, contact Mapi Research Trust.

Growth Hormone Deficiency - Child Treatment Burden Measure - Observer GHD-CTB - Observer)

Copyright: Novo Nordisk

Disease / Condition: growth hormone deficiency (GHD)

Population, Age: children diagnosed with growth hormone deficiency aged 4 to < 9 years (respondent: adult parent/guardian)

Type of Clinical Outcome Assessment: ObsRO measure

Outcome assessed: treatment burden

  • Domains (n=3): Physical, Emotional well-being, and Interference
    Number of items: 14
    Recall: past week
    Language of Development: English for USA

    1. Brod, M., Højbjerre, L., Alolga, S.L., Beck, J.F., Wilkinson, L., Rasmussen, M.H. Understanding treatment burden for children treated for growth hormone deficiency.Patient. 2017 Oct;10(5):653-666. doi: 10.1007/s40271-017-0237-9.

    2. Brod, M., Rasmussen, M.H., Alolga, S., Beck, J.F., Bushnell, D.M., Lee, K.W., Maniatis, A. Psychometric validation of the Growth Hormone Deficiency-Child Treatment Burden Measure (GHD-CTB) and the Growth Hormone Deficiency-Parent Treatment Burden Measure (GHD-PTB). Pharmacoecon Open. 2023 Jan;7(1):121-138. doi: 10.1007/s41669-022-00373-z.

  • Contact Mapi Research Trust.

For more information on this measure, for use and/or licensing, contact Mapi Research Trust.

Growth Hormone Deficiency - Parent Treatment Burden Measure (GHD-PTB)

Copyright: Novo Nordisk

Disease / Condition: growth hormone deficiency (GHD)

Population, Age: adult parent/guardian of child aged 4 to < 13 years diagnosed with growth hormone deficiency

Type of Clinical Outcome Assessment: PRO measure to assess treatment burden of parent/guardian living with a child diagnosed with growth hormone deficiency.

Outcome assessed: treatment burden

  • Domains (n=2): Emotional well-being and Interference
    Number of items: 8
    Recall: past week
    Language of Development: English for USA

    1. Brod, M., Rasmussen, M.H., Alolga, S., Beck, J.F., Bushnell, D.M., Lee, K.W., Maniatis, A. Psychometric validation of the Growth Hormone Deficiency-Child Treatment Burden Measure (GHD-CTB) and the Growth Hormone Deficiency-Parent Treatment Burden Measure (GHD-PTB). Pharmacoecon Open. 2023 Jan;7(1):121-138. doi: 10.1007/s41669-022-00373-z.

  • Contact Mapi Research Trust.

For more information on this measure, for use and/or licensing, contact Mapi Research Trust.

Treatment-Related Impact Measure - Adult Growth Hormone Deficiency (TRIM - AGHD)

Copyright: Novo Nordisk

Disease / Condition: growth hormone deficiency (GHD)

Population, Age: adult

Type of Clinical Outcome Assessment: PRO measure assessing growth hormone deficiency impacts.

Outcome assessed: health-related quality of life

  • Domains (n=4): Energy level, Physical health, Emotional health, Cognitive ability
    Number of items: 26
    Recall: current experience
    Language of Development: English for USA

    1. Brod, M., Hojbjerre, L., Adalsteinsson, J.E., Rasmussen, M. H. Assessing the impact of growth hormone deficiency and treatment in adults: Development of a new disease-specific measure. J Clin Endocrinol Metab. 2014;99(4):1204-1212. doi: 10.1210/jc.2013-3438.

    2. Brod, M., Pohlman, B., Hojbjerre, L., Adalsteinsson, J.E., Rasmussen, M.H. Impact of adult growth hormone deficiency on daily functioning and well-being. BMC Res Notes. 2014:7; 813. doi: 10.1186/1756-0500-7-813.

    3. Brod, M., Beck, J.F., Højbjerre, L., Bushnell, D.M., Adalsteinsson, J.E., Wilkinson, L., Rasmussen, M.H. Assessing the impact of Growth Hormone Deficiency (GHD) in adults: Interpreting change of the Treatment-Related Impact Measure-Adult Growth Hormone Deficiency (TRIM-AGHD). Pharmacoecon Open. 2019 Mar;3(1):71-80. doi: 10.1007/s41669-018-0082-3.

  • Contact Mapi Research Trust.

For more information on this measure, for use and/or licensing, contact Mapi Research Trust.